[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 51 of about 51

Advertisement
4. Sonabend RY, McKay SV, Okcu MF, Yan J, Haymond MW, Margolin JF: Hyperglycemia during induction therapy is associated with increased infectious complications in childhood acute lymphocytic leukemia. Pediatr Blood Cancer; 2008 Sep;51(3):387-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperglycemia during induction therapy is associated with increased infectious complications in childhood acute lymphocytic leukemia.
  • BACKGROUND: Children with acute lymphocytic leukemia (ALL) are at high risk for developing hyperglycemia.
  • [MeSH-major] Hyperglycemia / complications. Infection / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18523991.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose
  •  go-up   go-down


5. Wiemels JL, Kang M, Chang JS, Zheng L, Kouyoumji C, Zhang L, Smith MT, Scelo G, Metayer C, Buffler P, Wiencke JK: Backtracking RAS mutations in high hyperdiploid childhood acute lymphoblastic leukemia. Blood Cells Mol Dis; 2010 Oct 15;45(3):186-91
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Backtracking RAS mutations in high hyperdiploid childhood acute lymphoblastic leukemia.
  • High hyperdiploidy is the single largest subtype of childhood acute lymphoblastic leukemia (ALL) and is defined by the presence of 51-68 chromosomes in a karyotype.
  • We screened for RAS mutations among 517 acute childhood leukemias (including 437 lymphocytic, of which 393 were B-cell subtypes) and found mutations in 30% of high hyperdiploids compared to only 10% of leukemias of other subtypes (P<0.0001).
  • While RAS mutations were previously associated with prior chemical exposures in childhood and adult leukemias, in this study RAS-mutated cases were not significantly associated with parental smoking when compared to study controls.
  • IGH rearrangements were backtracked in three RAS-positive patients (which were negative for KRAS mutation at birth) and found to be evident before birth, confirming a prenatal origin for the leukemia clone.
  • We posit a natural history for hyperdiploid leukemia in which prenatal mitotic catastrophe is followed by a postnatal RAS mutation to produce the leukemic cell phenotype.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Leuk Res. 2006 Sep;30(9):1085-9 [16533526.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1565-8 [18024407.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6803-9 [18701506.001]
  • [Cites] Leukemia. 2008 Sep;22(9):1692-7 [18548099.001]
  • [Cites] Radiat Prot Dosimetry. 2008;132(2):212-9 [18940823.001]
  • [Cites] Leukemia. 2010 May;24(5):924-31 [20237506.001]
  • [Cites] Clin Chem. 2000 May;46(5):620-4 [10794742.001]
  • [Cites] Blood. 2000 Jul 1;96(1):264-8 [10891460.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2992-6 [11929791.001]
  • [Cites] Br J Cancer. 2002 May 6;86(9):1419-24 [11986774.001]
  • [Cites] Blood. 2002 Jul 1;100(1):347-9 [12070048.001]
  • [Cites] Environ Health Perspect. 2002 Sep;110(9):955-60 [12204832.001]
  • [Cites] Genes Chromosomes Cancer. 2004 May;40(1):38-43 [15034866.001]
  • [Cites] Leukemia. 2004 Apr;18(4):685-92 [14990973.001]
  • [Cites] Blood. 2004 May 1;103(9):3544-6 [14670924.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1230-5 [15247135.001]
  • [Cites] Blood. 1992 Jul 1;80(1):203-8 [1351763.001]
  • [Cites] Leukemia. 1993 Mar;7(3):349-60 [8445941.001]
  • [Cites] Leukemia. 1996 Feb;10(2):213-24 [8637229.001]
  • [Cites] Genes Chromosomes Cancer. 1996 May;16(1):40-5 [9162196.001]
  • [Cites] Leukemia. 2005 Mar;19(3):415-9 [15674422.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Oct;44(2):113-22 [15942938.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):578-81 [16537719.001]
  • [Cites] Am J Epidemiol. 2006 Jun 15;163(12):1091-100 [16597704.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):26-33 [17910045.001]
  • (PMID = 20688547.001).
  • [ISSN] 1096-0961
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P42-ES04705; United States / NCI NIH HHS / CA / R01 CA089032; United States / NIEHS NIH HHS / ES / P42 ES004705; United States / NCI NIH HHS / CA / R25 CA112355; United States / NCI NIH HHS / CA / R25-CA112355; United States / NIEHS NIH HHS / ES / R01-ES09137; United States / NIEHS NIH HHS / ES / P01 ES018172; United States / NCI NIH HHS / CA / R01-CA089032; United States / NIEHS NIH HHS / ES / P01-ES018172; United States / NIEHS NIH HHS / ES / R01 ES009137
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS224426; NLM/ PMC2943008
  •  go-up   go-down


6. da Costa Moraes CA, Trompieri NM, Cavalcante Felix FH: Pediatric acute promyelocytic leukemia: all-transretinoic acid therapy in a Brazilian pediatric hospital. J Pediatr Hematol Oncol; 2008 May;30(5):387-90
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric acute promyelocytic leukemia: all-transretinoic acid therapy in a Brazilian pediatric hospital.
  • Acute promyelocytic leukemia (APL) is an uncommon form of pediatric acute nonlymphocytic leukemia.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Agents / toxicity. Brazil. Female. Hospitals, Pediatric. Humans. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458575.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


7. Ribeiro KB, Buffler PA, Metayer C: Socioeconomic status and childhood acute lymphocytic leukemia incidence in São Paulo, Brazil. Int J Cancer; 2008 Oct 15;123(8):1907-12
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Socioeconomic status and childhood acute lymphocytic leukemia incidence in São Paulo, Brazil.
  • To investigate the association of childhood ALL and SES, we collected data on 507 children aged 0-14 years diagnosed with ALL between 1997 and 2002 from the population-based Cancer Registry of São Paulo, Brazil, covering 96 districts.
  • Lower incidence rates of childhood ALL were also found in areas with high percentages of households with more than 7 persons (>or=5.7%) compared with areas where there were <or=2.2% (RR = 0.32, 95% CI 0.25-0.43).
  • Population-based attributes for SES and household size may be useful surrogate markers of early exposure to childhood infections, which has been found to decrease the risk of ALL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688860.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Zhang ZX, Cao LZ, Huang Q, Yang MH, Wang Z, Yu Y: [Detection of human cyclin C gene expression in childhood acute lymphocytic leukemia using real-time fluorescence quantitative PCR]. Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb;10(1):14-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of human cyclin C gene expression in childhood acute lymphocytic leukemia using real-time fluorescence quantitative PCR].
  • OBJECTIVE: To explore the relationship between human cyclin C (CCNC) gene and childhood acute lymphocytic leukemia (ALL).
  • METHODS: The total RNA isolated from myeloid tissues of normal children and of children with newly diagnosed ALL and from ALL cell line 6T-CEM was reversely transcribed into cDNA.
  • RESULTS: CCNC was expressed in myeloid tissues of normal children and of children with newly diagnosed ALL as well as 6T-CEM.
  • CONCLUSIONS: CCNC gene shows lower expression in children with newly diagnosed ALL, suggesting that it may be a tumor suppressing gene in childhood ALL.
  • [MeSH-major] Cyclins / genetics. Polymerase Chain Reaction / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289462.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CCNC protein, human; 0 / Cyclin C; 0 / Cyclins
  •  go-up   go-down


9. Catusse J, Wollner S, Leick M, Schröttner P, Schraufstätter I, Burger M: Attenuation of CXCR4 responses by CCL18 in acute lymphocytic leukemia B cells. J Cell Physiol; 2010 Nov;225(3):792-800
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Attenuation of CXCR4 responses by CCL18 in acute lymphocytic leukemia B cells.
  • Elevated levels of CCL18 have been described in various diseases including childhood acute lymphocytic leukemia (ALL) but its functions remain poorly characterized.
  • [MeSH-major] Chemokines, CC / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cells, B-Lymphoid / immunology. Receptors, CXCR4 / metabolism. Signal Transduction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc.
  • (PMID = 20568229.001).
  • [ISSN] 1097-4652
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCL18 protein, human; 0 / CXCL12 protein, human; 0 / CXCR4 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CC; 0 / Estrogen Antagonists; 0 / GPER protein, human; 0 / Ligands; 0 / Receptors, CXCR4; 0 / Receptors, Estrogen; 0 / Receptors, G-Protein-Coupled; 0 / Recombinant Proteins; 4TI98Z838E / Estradiol
  •  go-up   go-down


10. Wang Z, Hu T, Cao LZ, Kang R, Zhao MY, Yu Y, Xu WQ: [Expression of WAVE1 in childhood acute lymphocytic leukemia and in the apoptosis of Jurkat cells induced by adriamycin]. Zhongguo Dang Dai Er Ke Za Zhi; 2008 Oct;10(5):620-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of WAVE1 in childhood acute lymphocytic leukemia and in the apoptosis of Jurkat cells induced by adriamycin].
  • OBJECTIVE: To investigate whether WASP/Verprolin homologous protein 1 (WAVE1) plays a role in the pathogenesis of childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Apoptosis / drug effects. Doxorubicin / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Wiskott-Aldrich Syndrome Protein Family / physiology

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18947485.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / RNA, Messenger; 0 / WASF1 protein, human; 0 / Wiskott-Aldrich Syndrome Protein Family; 80168379AG / Doxorubicin
  •  go-up   go-down


11. Nurzyńska-Flak J, Kowalczyk JR: [Incidence of childhood leukemia in the Lublin region of Poland in 1988-2000]. Wiad Lek; 2005;58(5-6):284-6
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidence of childhood leukemia in the Lublin region of Poland in 1988-2000].
  • Purpose of the work was the analysis of the number and structure of leukemia in children living in the Lublin Region of Poland.
  • Among leukemias, according to the International Classification of Childhood Cancers, were counted: lymphoid leukemia, acute non-lymphocytic leukemia, chronic myeloid leukemia, other specified and unspecified leukemias.
  • RESULTS: 244 cases of leukemia were reported (152 boys--62.3% and 92 girls--37.7%).
  • CONCLUSIONS: In the Lublin Region lower percentage of leukemia was observed compared to the values determined for the country.
  • Incidence of leukemia was falling, but the analysis in age-groups proved, that it was caused by the decreasing incidence in children under 5 year.
  • [MeSH-major] Leukemia / epidemiology

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16238118.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


12. Bener A, Hoffmann GF, Afify Z, Rasul K, Tewfik I: Does prolonged breastfeeding reduce the risk for childhood leukemia and lymphomas? Minerva Pediatr; 2008 Apr;60(2):155-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does prolonged breastfeeding reduce the risk for childhood leukemia and lymphomas?
  • AIM: Prolonged breastfeeding was shown to reduce the risk of childhood acute leukemia.
  • The aim of the study was to investigate the protective effect of longer breastfeeding on the risk of lymphoid malignancies in children and its dependent socio-economic factors.
  • METHODS: The study group comprised of 169 patients with acute lymphocytic leukemia (ALL), Hodgkin's (HL) and non-Hodgkin's lymphoma (NHL), age =or<15 years, and 169 healthy controls, matched to patients by age and sex.
  • In multivariate analysis, statistically significant risk factors for the development of childhood lymphoid malignancy were: a shorter duration of breastfeeding, lower age and level of education of mother and higher income, larger size of accommodation and birth order in the family.
  • All these factors can be related to an increased risk of early childhood infections.
  • [MeSH-major] Breast Feeding. Hodgkin Disease / prevention & control. Lymphoma, Non-Hodgkin / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control

  • MedlinePlus Health Information. consumer health - Breastfeeding.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18449131.001).
  • [ISSN] 0026-4946
  • [Journal-full-title] Minerva pediatrica
  • [ISO-abbreviation] Minerva Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


13. Luo CY, Li BS, Jiang H, Gu LJ: [Study of the correlation between the expression level of asparagine synthetase and the outcome of children with acute lymphocytic leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2008 Jul;29(7):446-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of the correlation between the expression level of asparagine synthetase and the outcome of children with acute lymphocytic leukemia].
  • OBJECTIVE: To determine whether the high level of asparagine synthetase (AS) expression in childhood acute lymphocytic leukemia (ALL) is associated with an inferior prognosis.
  • [MeSH-major] Aspartate-Ammonia Ligase / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035175.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 6.3.1.1 / Aspartate-Ammonia Ligase
  •  go-up   go-down


14. Stachel D, Albert M, Meilbeck R, Paulides M, Schmid I: Expression of angiogenic factors in childhood B-cell precursor acute lymphoblastic leukemia. Oncol Rep; 2007 Jan;17(1):147-52
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of angiogenic factors in childhood B-cell precursor acute lymphoblastic leukemia.
  • In pediatric acute lymphocytic leukemia however, the expression of angiogenic molecules and its relation to prognosis and relapse are unknown.
  • Therefore, we prospectively analyzed 46 pediatric patients with precursor B cell acute lymphocytic leukemia by semi-quantitative RT-PCR for expression of the angiogenic molecules VEGF, VEGF-C, iNOS and TGF-beta and correlated relapse and survival data with the expression of these factors.
  • A significantly higher mRNA expression of iNOS was found in surviving patients compared with non-surviving patients (p=0.023).
  • Angiogenic factors are expressed in the bone marrow of patients with pediatric B cell precursor ALL and VEGF is a potential candidate for therapeutic intervention as it is significantly higher expressed in children with late relapses.
  • The mRNA expression of iNOS in the surviving children possibly reflects an increased activity of the immune system against the leukemia which leads to a superior survival.
  • [MeSH-major] Angiogenic Proteins / biosynthesis. Burkitt Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143492.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiogenic Proteins; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 103107-01-3 / Fibroblast Growth Factor 2; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  •  go-up   go-down


15. Altinkaynak S, Selimoglu MA, Turgut A, Kilicaslan B, Ertekin V: Breast-feeding duration and childhood acute leukemia and lymphomas in a sample of Turkish children. J Pediatr Gastroenterol Nutr; 2006 May;42(5):568-72
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast-feeding duration and childhood acute leukemia and lymphomas in a sample of Turkish children.
  • OBJECTIVES: Whether breast-feeding is associated with decreased incidence of the lymphoid malignancies in children is uncertain.
  • We evaluated childhood acute leukemia and lymphoma in relation to duration of breast-feeding.
  • METHODS: We investigated this issue in a case-control study comprising 137 patients, aged 1 to 16 years, with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin or non-Hodgkin lymphoma, in addition to 146 controls matched for age and sex.
  • Breast-feeding for a duration of 0 to 6 months, when compared with feeding of longer than 6 months, was associated with increased odds ratios (ORs) for ALL [OR = 2.44, 95% confidence interval (CI) = 1.17-5.10], AML (OR = 6.67, 95% CI = 1.32-33.69), Hodgkin lymphoma (OR = 3.33, 95% CI = 0.60-18.54), non-Hodgkin lymphoma (OR = 1.90, 95% CI = 0.68-5.34) and overall (OR = 2.54, 95% CI = 1.51-4.26).
  • CONCLUSIONS: Our findings suggest that breast-feeding of more than 6 months is protective against childhood lymphoid malignancies, especially for AML and ALL.
  • [MeSH-major] Breast Feeding. Leukemia / prevention & control. Lymphoma / prevention & control
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Female. Humans. Infant. Male. Risk Factors. Time Factors. Turkey

  • MedlinePlus Health Information. consumer health - Breastfeeding.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707982.001).
  • [ISSN] 1536-4801
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Karimi M, Mehrabani D, Yarmohammadi H, Jahromi FS: The prevalence of signs and symptoms of childhood leukemia and lymphoma in Fars Province, Southern Iran. Cancer Detect Prev; 2008;32(2):178-83
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prevalence of signs and symptoms of childhood leukemia and lymphoma in Fars Province, Southern Iran.
  • BACKGROUND: Leukemia and lymphomas are still the common childhood cancers in Iran.
  • This study was undertaken to determine the prevalence of signs and symptoms of these malignancies in children of Fars Province, Southern Iran.
  • METHODS: A total of 368 cases of children who were less than 15 years old and diagnosed as acute lymphocytic leukemia (ALL, n=211), acute myeloid leukemia (AML, n=64), Burkitt lymphoma (BL, n=40), chronic myeloid leukemia (CML, n=5), Hodgkin's disease (HD, n=33) or non-Burkitt-type, non-Hodgkin's lymphoma (NBNHL, n=15) referring to the hospitals of Shiraz University of Medical Sciences from April 1997 to March 2002 were enrolled.
  • CONCLUSION: Knowledge of signs and symptoms and types of presentations of childhood leukemia and lymphoma may help a physician to improve the patient's outcome.
  • This study revealed that attention to uncommon signs and symptoms in history taking and physical examination together with laboratory tests may increase the physicians' awareness and better diagnosis of pediatric malignancies and would also be beneficial for the patient.
  • [MeSH-major] Leukemia / diagnosis. Leukemia / epidemiology. Lymphoma / diagnosis. Lymphoma / epidemiology

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18632219.001).
  • [ISSN] 1525-1500
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


17. Hou Y, Hu Q, Liu AG, Zhang LQ, Liu SY: [Expression of survivin and its location in bone marrow cells of childhood acute leukemia: relationship to therapeutic efficacy]. Zhongguo Dang Dai Er Ke Za Zhi; 2006 Apr;8(2):101-4
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of survivin and its location in bone marrow cells of childhood acute leukemia: relationship to therapeutic efficacy].
  • METHODS: The expression of survivin protein was detected by immunohistochemical assay in bone marrow cells from 62 children with acute leukemia and 40 hospitalized children who did not have leukemia (Control group), and in a human acute T lymphocytic leukemia cell line (Molt-4 cells) treated in vitro with daunorubicin (DNR).
  • RESULTS: Survivin protein was expressed in 41.9% of the 62 children with acute leukemia but in only 5.0% of the Control group (chi(2)=16.66; P < 0.01).
  • The expression rate of survivin was 46.2% in cytoplasm and 53.9% in nucleus in the children with acute leukemia (chi(2)0.3077; P> 0.05).
  • CONCLUSIONS: Survivin may play an important role in the development and prognosis of childhood acute leukemia.
  • The different expression pattern of survivin in the cytoplasm and the nucleus may be associated with therapeutic efficacy and prognosis in acute leukemia.
  • [MeSH-major] Bone Marrow Cells / chemistry. Daunorubicin / therapeutic use. Leukemia, Myeloid, Acute / metabolism. Microtubule-Associated Proteins / analysis. Neoplasm Proteins / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613699.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


18. Stachel D, Albert M, Meilbeck R, Kreutzer B, Haas RJ, Schmid I: Bone marrow Th2 cytokine expression as predictor for relapse in childhood acute lymphoblastic leukemia (ALL). Eur J Med Res; 2006 Mar 27;11(3):102-13
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow Th2 cytokine expression as predictor for relapse in childhood acute lymphoblastic leukemia (ALL).
  • Samples from 49 consecutive pediatric patients with B cell precursor acute lymphocytic leukemia (BCP ALL) were analyzed by semiquantitative RT-PCR.
  • We identified interleukin (IL)-10 expression as a significant adverse prognostic indicator in childhood BCP-ALL.
  • These findings emphasize the role of the immune system for the outcome of childhood ALL.
  • [MeSH-major] Bone Marrow Cells / immunology. Burkitt Lymphoma / genetics. Burkitt Lymphoma / immunology. Cytokines / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Th2 Cells / immunology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16751110.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD86; 0 / CD86 protein, human; 0 / Cytokines; 0 / Interleukin-1; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 130068-27-8 / Interleukin-10; 207137-56-2 / Interleukin-4
  •  go-up   go-down


19. Wandroo F, Bell A, Darbyshire P, Pratt G, Stankovic T, Gordon J, Lawson S, Moss P: ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia. Int J Lab Hematol; 2008 Apr;30(2):149-57
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia.
  • ZAP-70 is, however, expressed in adult B cell chronic lymphocytic leukemia where it correlates with a poor prognosis.
  • We wished to determine if ZAP-70 is also expressed in pediatric B cell malignancy.
  • ZAP-70 expression was then determined in bone marrow lymphoblasts obtained from 12 patients with pre-B cell acute lymphoblastic leukemia (ALL).
  • ZAP-70 expression was strongly expressed in nine of the 12 cases of primary pre-B cell lymphoblastic leukemia.
  • The T cell-associated protein kinase ZAP-70 is highly expressed in pre-B lineage cells and most cases of pre-B acute lymphoblastic leukemia.
  • [MeSH-major] B-Lymphocytes / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cells, B-Lymphoid / metabolism. ZAP-70 Protein-Tyrosine Kinase / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18333847.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


20. Ward MH, Colt JS, Metayer C, Gunier RB, Lubin J, Crouse V, Nishioka MG, Reynolds P, Buffler PA: Residential exposure to polychlorinated biphenyls and organochlorine pesticides and risk of childhood leukemia. Environ Health Perspect; 2009 Jun;117(6):1007-13
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residential exposure to polychlorinated biphenyls and organochlorine pesticides and risk of childhood leukemia.
  • BACKGROUND: Incidence of childhood leukemia in industrialized countries rose significantly during 1975-2004, and the reasons for the increase are not understood.
  • OBJECTIVES: We used carpet dust as an exposure indicator to examine the risk of childhood leukemia in relation to residential exposure to persistent organochlorine chemicals: six polychlorinated biphenyl (PCB) congeners and the pesticides alpha- and gamma-chlordane, p,p'-DDT (dichlorodiphenyltrichloroethane), p,p'-DDE (dichlorodiphenyldichloroethylene), methoxychlor, and pentachlorophenol.
  • The study included 184 acute lymphocytic leukemia (ALL) cases 0-7 years of age and 212 birth certificate controls matched to cases by birth date, sex, race, and Hispanic ethnicity.
  • The associations with PCBs were stronger among non-Hispanic whites than among Hispanics despite similar distributions of PCB levels among controls in each racial/ethnic group.
  • CONCLUSIONS: Our findings suggest that PCBs, which are considered probable human carcinogens and cause perturbations of the immune system, may represent a previously unrecognized risk factor for childhood leukemia.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Pesticides.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Expo Anal Environ Epidemiol. 2001 Nov-Dec;11(6):449-58 [11791162.001]
  • [Cites] Environ Health. 2008;7:2 [18201376.001]
  • [Cites] Environ Health Perspect. 2003 Jul;111(9):1235-41 [12842779.001]
  • [Cites] Environ Health Perspect. 2004 Apr;112(5):631-5 [15064173.001]
  • [Cites] Am J Epidemiol. 2004 May 15;159(10):915-21 [15128601.001]
  • [Cites] Environ Health Perspect. 2004 Jul;112(10):1051-3 [15238275.001]
  • [Cites] Scand J Work Environ Health. 1978 Jun;4(2):137-50 [278225.001]
  • [Cites] Teratog Carcinog Mutagen. 1987;7(6):527-40 [2893466.001]
  • [Cites] Regul Toxicol Pharmacol. 1989 Oct;10(2):123-37 [2813865.001]
  • [Cites] Arch Environ Health. 1990 Mar-Apr;45(2):112-22 [2334233.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6585-91 [2208120.001]
  • [Cites] Environ Health Perspect. 1990 Nov;89:55-60 [2088756.001]
  • [Cites] Eur J Pediatr. 1992 Nov;151(11):802-5 [1468452.001]
  • [Cites] Environ Health Perspect. 1993 Apr;100:259-68 [8354174.001]
  • [Cites] Exp Clin Immunogenet. 1994;11(2-3):149-62 [7826664.001]
  • [Cites] Fundam Appl Toxicol. 1995 Aug;27(1):131-9 [7589923.001]
  • [Cites] Int J Cancer. 1996 Jul 29;67(3):323-6 [8707403.001]
  • [Cites] Am J Public Health. 1996 Oct;86(10):1416-21 [8876511.001]
  • [Cites] Environ Health Perspect. 1997 Jan;105(1):13-4 [9074863.001]
  • [Cites] J Expo Anal Environ Epidemiol. 1997 Apr-Jun;7(2):217-34 [9185013.001]
  • [Cites] Environ Health Perspect. 1997 Oct;105(10):1068-77 [9349828.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;69:1-631 [9379504.001]
  • [Cites] Environ Health Perspect. 1998 Jun;106 Suppl 3:893-908 [9646054.001]
  • [Cites] Environ Health Perspect. 1999 Jan;107(1):75-81 [9872720.001]
  • [Cites] Environ Health Perspect. 2004 Dec;112(17):1691-6 [15579415.001]
  • [Cites] J Occup Environ Med. 2005 Mar;47(3):199-211 [15761315.001]
  • [Cites] Cancer Invest. 2005;23(1):60-75 [15779869.001]
  • [Cites] Epidemiology. 2005 Jul;16(4):516-25 [15951670.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1928-34 [16103439.001]
  • [Cites] Haematologica. 2005 Sep;90(9):1197-204 [16154843.001]
  • [Cites] J Toxicol Environ Health A. 2005 Nov 26;68(22):1977-93 [16263690.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11214-26 [16322272.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 15;98(6):417-20 [16537835.001]
  • [Cites] Am J Epidemiol. 2006 Jun 15;163(12):1091-100 [16597704.001]
  • [Cites] Mol Nutr Food Res. 2006 Oct;50(10):922-33 [17009213.001]
  • [Cites] Int J Cancer. 2007 Feb 1;120(3):642-9 [17096337.001]
  • [Cites] Chemosphere. 2007 Apr;67(9):S307-17 [17280703.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):71-4 [17366822.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):373-6 [17337641.001]
  • [Cites] Environ Health Perspect. 2007 Feb;115(2):173-5 [17384760.001]
  • [Cites] Scand J Work Environ Health. 2007 Aug;33(4):293-303 [17717622.001]
  • [Cites] Environ Health Perspect. 2007 Sep;115(9):1271-5 [17805415.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2007 Jan-Mar;10(1-2):81-99 [18074305.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2008 Feb;102(2):146-54 [18226068.001]
  • [Cites] Environ Health. 2008;7:6 [18291036.001]
  • [Cites] Rev Environ Contam Toxicol. 2002;175:1-46 [12206053.001]
  • (PMID = 19590698.001).
  • [ISSN] 1552-9924
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA092683; United States / NIEHS NIH HHS / ES / R01ES009137; United States / NCI NIH HHS / CP / N02CP11015; United States / NIEHS NIH HHS / ES / P42 ES004705; United States / Intramural NIH HHS / / ; United States / NIEHS NIH HHS / ES / P-42-ES-04705-18; United States / NIEHS NIH HHS / ES / R01 ES009137; United States / NCI NIH HHS / CP / N02-CP-11015; United States / NCI NIH HHS / CA / 5R01CA092683-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Environmental Pollutants; 0 / Hydrocarbons, Chlorinated; 0 / Pesticides; DFC2HB4I0K / Polychlorinated Biphenyls
  • [Other-IDs] NLM/ PMC2702395
  • [Keywords] NOTNLM ; childhood cancer / dust / leukemia / organochlorine compounds / pesticides / polychlorinated biphenyls
  •  go-up   go-down


21. Franco A, Lewis KN, Blackmon JM, Manaloor EJ: Hyperostosis - an unusual radiographic presentation of Myelodysplastic Syndrome transformed to Acute Myeloid Leukemia. J Radiol Case Rep; 2010;4(11):18-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperostosis - an unusual radiographic presentation of Myelodysplastic Syndrome transformed to Acute Myeloid Leukemia.
  • Acute myeloid leukemia (AML) is also referred to non-lymphocytic leukemia in the literature.
  • It comprises about 15% of the childhood leukemia.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22470698.001).
  • [ISSN] 1943-0922
  • [Journal-full-title] Journal of radiology case reports
  • [ISO-abbreviation] J Radiol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3303354
  • [Keywords] NOTNLM ; Acute myeloid leukemia / Hyperostosis / Myelodysplastic Syndrome
  •  go-up   go-down


22. Troeger A, Siepermann M, Escherich G, Meisel R, Willers R, Gudowius S, Moritz T, Laws HJ, Hanenberg H, Goebel U, Janka-Schaub GE, Mahotka C, Dilloo D: Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica; 2007 Aug;92(8):1043-50
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia.
  • Overexpression of survivin was found to correlate with poor prognosis in a variety of cancers including hematologic malignancies.
  • To date, however, there is no information available on the prognostic role of survivin in pediatric precursor B-cell acute lymphocytic leukemia (BCP-ALL), the most frequent malignancy in childhood.
  • DESIGN AND METHODS: In a retrospective study including 66 pediatric patients we analyzed the impact of survivin protein levels on outcome in BCP-ALL.
  • RESULTS: Survivin overexpression, with an up to ten-fold increase of the normal level, was detected in 65% of the leukemic samples in contrast to negligible expression in non-malignant hematopoietic cells.
  • [MeSH-major] Inhibitor of Apoptosis Proteins / analysis. Microtubule-Associated Proteins / analysis. Neoplasm Proteins / analysis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640858.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


23. Tigay JH: A comparison of acute lymphoblastic leukemia in Down syndrome and non-Down syndrome children: the role of trisomy 21. J Pediatr Oncol Nurs; 2009 Nov-Dec;26(6):362-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of acute lymphoblastic leukemia in Down syndrome and non-Down syndrome children: the role of trisomy 21.
  • Among the many aberrations caused by DS, including shortened stature and distorted facies, are several blood dyscrasias, including childhood leukemias-namely, acute myeloid leukemia (AML) and acute lymphoblastic, or lymphocytic, leukemia (ALL).
  • ALL is associated with an inherited trisomy 21 in DS children (ALL-DS) and with acquired trisomies, +21, 8, and 13, in non-DS children (ALL-NDS).
  • Other mutations are the gene fusion at TEL/AML1, and a new mutation found, which labels the Janus Kinase gene or JAK2 as on oncogenic precursor, which when associated with the B-cell precursor gene or BCP is highly leukomogenic.
  • [MeSH-major] Down Syndrome / complications. Down Syndrome / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


24. Zhang JB, Sun Y, Dong J, Liu LX, Ning F: [Expression of lung resistance protein and multidrug resistance-associated protein in naive childhood acute leukemia and their clinical significance]. Ai Zheng; 2005 Aug;24(8):1015-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of lung resistance protein and multidrug resistance-associated protein in naive childhood acute leukemia and their clinical significance].
  • BACKGROUND & OBJECTIVE: Previous studies revealed that lung resistance protein (LRP) and multidrug resistance-associated protein (MRP) relate to drug resistance of childhood leukemia, which is not caused by only one mechanism.
  • This study was to evaluate the expression of LRP and MRP genes in childhood leukemia and their correlation.
  • METHODS: The expression of LRP and MRP in 38 children with acute leukemia and 6 healthy children were measured with reverse transcription-polymerase chain reaction (RT-PCR); their clinical significance was analyzed according to complete remission (CR) rate of the patients after chemotherapy.
  • The positive rate of LRP was significantly lower in acute lymphoblastic leukemia (ALL) than in acute nonlymphocytic leukemia (ANLL) [18.5% (5/27) vs. 45.5% (6/11), P < 0.05]; however, the positive rate of MRP was 59.3% (16/27) in ALL, and 45.5% (5/11) in ANLL (P > 0.05).
  • CONCLUSION: Childhood acute leukemia patients with overexpression of LRP and MRP suffer severe disease and achieve low remission rateû lower remission rate of childhood ANLL patients may relate to LRP expression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / metabolism. Multidrug Resistance-Associated Proteins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Vault Ribonucleoprotein Particles / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086885.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Multidrug Resistance-Associated Proteins; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein
  •  go-up   go-down


28. Dama E, Pastore G, Mosso ML, Maule MM, Zuccolo L, Magnani C, Merletti F: Time trends and prognostic factors for survival from childhood cancer: a report from the Childhood Cancer Registry of Piedmont (Italy). Eur J Pediatr; 2006 Apr;165(4):240-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time trends and prognostic factors for survival from childhood cancer: a report from the Childhood Cancer Registry of Piedmont (Italy).
  • Survival after childhood cancer has been improving since the late 1970s in most developed countries.
  • The Childhood Cancer Registry of Piedmont has been recording malignant tumors in children (0-14 years) throughout Piedmont since 1967.
  • For acute lymphocytic leukemia, the survival rate increased steadily from 24.7% (95% CI 15.0-34.3) in 1970-1974 to 87.8% (82.1-93.6) in 1995-1999.
  • The extent of disease at diagnosis was related to prognosis for neuroblastoma and ganglioneuroblastoma and other selected solid tumors.
  • A white blood cell count greater than 50,000 x 10(6) cells/l was associated with decreased survival in children with acute lymphocytic leukemia and acute non-lymphocytic leukemia.
  • We have found positive trends in survival for all tumor types in Piedmont, similar to those reported by other population-based cancer registries.
  • [MeSH-major] Leukemia / mortality. Neoplasms / mortality. Registries


29. Schmitz NM, Hirt A, Aebi M, Leibundgut K: Limited redundancy in phosphorylation of retinoblastoma tumor suppressor protein by cyclin-dependent kinases in acute lymphoblastic leukemia. Am J Pathol; 2006 Sep;169(3):1074-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited redundancy in phosphorylation of retinoblastoma tumor suppressor protein by cyclin-dependent kinases in acute lymphoblastic leukemia.
  • In Nalm-6 acute lymphoblastic leukemia extracts, serine 608 is phosphorylated by CDK4/6 complexes but not by CDK2.
  • Serine 612 phosphorylation by CDK4 also occurred in extracts of childhood acute lymphoblastic leukemia cells but not in extracts of mobilized CD34+ hemopoietic progenitor cells.
  • This phenomenon could contribute to the commitment of childhood acute lymphocytic leukemia cells to proliferate and explain their refractoriness to differentiation-inducing agents.
  • [MeSH-major] Burkitt Lymphoma / metabolism. Cyclin-Dependent Kinase 2 / metabolism. Cyclin-Dependent Kinase 4 / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Protein Processing, Post-Translational. Retinoblastoma-Like Protein p107 / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Retinoblastoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Jan 27;19(4):562-70 [10698526.001]
  • [Cites] Cell. 2000 Mar 31;101(1):79-89 [10778858.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4320-3 [10969768.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Sep 7;275(3):877-84 [10973815.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19358-66 [12646568.001]
  • [Cites] Cell. 2003 Aug 22;114(4):431-43 [12941272.001]
  • [Cites] Nat Genet. 2003 Sep;35(1):25-31 [12923533.001]
  • [Cites] EMBO J. 2003 Sep 15;22(18):4794-803 [12970191.001]
  • [Cites] Curr Biol. 2003 Oct 14;13(20):1775-85 [14561402.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):27-36 [14700606.001]
  • [Cites] Biochem Biophys Res Commun. 2004 May 7;317(3):779-86 [15081408.001]
  • [Cites] Cell. 2004 Apr 16;117(2):239-51 [15084261.001]
  • [Cites] Cell. 2004 Aug 20;118(4):477-91 [15315760.001]
  • [Cites] Cell. 2004 Aug 20;118(4):493-504 [15315761.001]
  • [Cites] Science. 1989 Nov 3;246(4930):603-8 [2683075.001]
  • [Cites] Cell. 1991 May 3;65(3):381-93 [2018973.001]
  • [Cites] Cell. 1991 Oct 18;67(2):293-302 [1655277.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):6914-8 [8346196.001]
  • [Cites] Mol Cell Biol. 1993 Oct;13(10):6501-8 [8413249.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):2066-76 [8114738.001]
  • [Cites] Leukemia. 1994 Jun;8(6):940-5 [8207988.001]
  • [Cites] Cell. 1994 Jul 15;78(1):161-72 [8033208.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3215-20 [8622916.001]
  • [Cites] Cell. 2005 Dec 16;123(6):1093-106 [16360038.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14317-22 [11114185.001]
  • [Cites] Leukemia. 2001 Jan;15(1):1-9 [11243375.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(14):4773-84 [11416152.001]
  • [Cites] Nature. 2001 Sep 6;413(6851):83-6 [11544530.001]
  • [Cites] EMBO Rep. 2001 Sep;2(9):794-9 [11520855.001]
  • [Cites] J Biochem Mol Biol. 2003 Jan 31;36(1):60-5 [12542976.001]
  • [Cites] J Biol Chem. 1996 Apr 5;271(14):8313-20 [8626527.001]
  • [Cites] Mol Cell Biol. 1996 Dec;16(12):7173-81 [8943373.001]
  • [Cites] EMBO J. 1996 Dec 16;15(24):7060-9 [9003781.001]
  • [Cites] Oncogene. 1997 Jan 16;14(2):249-54 [9010227.001]
  • [Cites] Br J Haematol. 1997 Feb;96(2):366-8 [9029026.001]
  • [Cites] Mol Biol Cell. 1997 Feb;8(2):287-301 [9190208.001]
  • [Cites] J Biol Chem. 1997 May 9;272(19):12738-46 [9139732.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] Mol Cell Biol. 1997 Oct;17(10):5771-83 [9315635.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10699-704 [9380698.001]
  • [Cites] Oncogene. 1997 Dec 4;15(23):2855-66 [9419977.001]
  • [Cites] Mol Cell Biol. 1998 Feb;18(2):753-61 [9447971.001]
  • [Cites] Carcinogenesis. 1998 May;19(5):765-9 [9635861.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10493-8 [9724731.001]
  • [Cites] J Biol Chem. 1999 Apr 2;274(14):9463-71 [10092628.001]
  • [Cites] Pediatr Res. 1999 May;45(5 Pt 1):692-6 [10231867.001]
  • [Cites] Cell. 1999 Sep 17;98(6):859-69 [10499802.001]
  • [Cites] Mol Cell. 2004 Dec 3;16(5):831-7 [15574337.001]
  • [Cites] J Biochem. 2005 Mar;137(3):381-6 [15809340.001]
  • [Cites] Cancer Cell. 2005 Jun;7(6):591-8 [15950907.001]
  • [Cites] Stem Cells. 2005 Aug;23(7):1002-11 [15941859.001]
  • [Cites] Nat Cell Biol. 2005 Aug;7(8):831-6 [16007079.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1400-6 [15878982.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1783-7 [16107892.001]
  • (PMID = 16936279.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Indoles; 0 / Multiprotein Complexes; 0 / Retinoblastoma-Like Protein p107; 114719-57-2 / fascaplysine; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  • [Other-IDs] NLM/ PMC1698824
  •  go-up   go-down


30. Siviero-Miachon AA, Spinola-Castro AM, Guerra-Junior G: Adiposity in childhood cancer survivors: insights into obesity physiopathology. Arq Bras Endocrinol Metabol; 2009 Mar;53(2):190-200
MedlinePlus Health Information. consumer health - Obesity in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adiposity in childhood cancer survivors: insights into obesity physiopathology.
  • As childhood cancer treatment has become more effective, survival rates have improved, and a number of complications have been described while many of these patients reach adulthood.
  • Currently, studies concerning overweight have focused on acute lymphocytic leukemia and brain tumors, since they are at risk for hypothalamic-pituitary axis damage secondary to cancer therapies (cranial irradiation, chemotherapy, and brain surgery) or to primary tumor location.
  • [MeSH-major] Adipose Tissue / physiopathology. Adiposity / physiology. Brain Neoplasms / therapy. Leukemia, Lymphoid / therapy. Obesity / physiopathology


31. Evrard AS, Hémon D, Billon S, Laurier D, Jougla E, Tirmarche M, Clavel J: Ecological association between indoor radon concentration and childhood leukaemia incidence in France, 1990-1998. Eur J Cancer Prev; 2005 Apr;14(2):147-57
Hazardous Substances Data Bank. RADON, RADIOACTIVE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ecological association between indoor radon concentration and childhood leukaemia incidence in France, 1990-1998.
  • The objective of this study was to evaluate the ecological association between indoor radon concentration and acute leukaemia incidence among children under 15 years of age in the 348 geographical units (zones d'emploi, ZE) of France between 1990 and 1998.
  • During that period, 4015 cases were registered by the French National Registry of Childhood Leukaemia and Lymphoma.
  • A positive ecological association, on the borderline of statistical significance (P=0.053), was observed between indoor radon concentration and childhood leukaemia incidence.
  • The association was highly significant for acute myeloid leukaemia (AML) (P=0.004) but not for acute lymphocytic leukaemia (ALL) (P=0.49).
  • The standardized incidence ratio (SIR) increased by 7, 3 and 24% for all acute leukaemia, ALL and AML, respectively, when radon concentration increased by 100 Bq/m.
  • In conclusion, the present ecological study supports the hypothesis of a moderate association between indoor radon concentration and childhood acute myeloid leukaemia.
  • [MeSH-major] Air Pollution, Indoor / adverse effects. Environmental Exposure. Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Radon / adverse effects. Registries / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Indoor Air Pollution.
  • MedlinePlus Health Information. consumer health - Radon.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15785319.001).
  • [ISSN] 0959-8278
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] Q74S4N8N1G / Radon
  •  go-up   go-down


32. Yamamoto JF, Goodman MT: Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control; 2008 May;19(4):379-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002.
  • OBJECTIVE: Efforts to prevent leukemia have been hampered by an inability to identify significant risk factors.
  • Exploring incidence patterns of leukemia subtypes by sex and race/ethnic group may generate new etiologic hypotheses and identify high-risk groups for further study.
  • METHODS: Data from the North American Association of Central Cancer Registries for 1997-2002 were used to assess patterns of leukemia incidence by subtype, sex, age, race and ethnicity.
  • RESULTS: A total of 144,559 leukemia cases were identified, including 66,067 (46%) acute and 71,860 (50%) chronic leukemias.
  • The highest rates of acute myeloid leukemia with and without maturation were observed in Asian-Pacific Islanders (API).
  • Hispanics had a higher incidence of acute lymphocytic leukemia, particularly in childhood, and promyelocytic leukemia than did non-Hispanics.
  • African-Americans had the highest rates of HTLV-1 positive adult T-cell leukemia/lymphoma.
  • A sharp increase in the incidence of chronic myeloid leukemia was observed for both APIs and Hispanics, 85 years and older.
  • CONCLUSION: Known risk factors are unlikely to explain the observed disparities in leukemia incidence.
  • Further studies of differences in environmental and genetic risk factors in these populations by specific leukemia subtype may provide clues to the etiologies of these malignancies.
  • [MeSH-major] Leukemia / ethnology

  • Genetics Home Reference. consumer health - acute promyelocytic leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064533.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  •  go-up   go-down


33. Whitworth KW, Symanski E, Coker AL: Childhood lymphohematopoietic cancer incidence and hazardous air pollutants in southeast Texas, 1995-2004. Environ Health Perspect; 2008 Nov;116(11):1576-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood lymphohematopoietic cancer incidence and hazardous air pollutants in southeast Texas, 1995-2004.
  • There is increasing interest in the role of air pollutants, including benzene and 1,3-butadiene, in the etiology of childhood cancers.
  • OBJECTIVE: Our goal was to assess whether census tracts with the highest benzene or 1,3-butadiene ambient air levels have increased childhood lymphohematopoietic cancer incidence.
  • METHODS: Our ecologic analysis included 977 cases of childhood lymphohematopoietic cancer diagnosed from 1995-2004.
  • RESULTS: Census tracts with the highest benzene levels had elevated rates of all leukemia [rate ratio (RR) = 1.37; 95% confidence interval (CI), 1.05, 1.78].
  • This association was higher for acute myeloid leukemia (AML) (RR = 2.02; 95% CI, 1.03-3.96) than for acute lymphocytic leukemia (ALL) (RR = 1.24; 95% CI, 0.92-1.66).
  • Among census tracts with the highest 1,3-butadiene levels, we observed RRs of 1.40 (95% CI, 1.07-1.81), 1.68 (95% CI, 0.84-3.35), and 1.32 (95% CI, 0.98-1.77) for all leukemia, AML, and ALL, respectively.
  • CONCLUSIONS: Our ecologic analysis suggests an association between childhood leukemia and hazardous air pollution; further research using more sophisticated methodology is warranted.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Air Waste Manag Assoc. 2000 Feb;50(2):175-80 [10680346.001]
  • [Cites] Occup Environ Med. 1999 Nov;56(11):774-80 [10658564.001]
  • [Cites] J Am Stat Assoc. 1995 Mar;90(429):64-71 [12155398.001]
  • [Cites] Cancer Causes Control. 2002 Sep;13(7):665-73 [12296514.001]
  • [Cites] Environ Health Perspect. 2003 Apr;111(4):663-8 [12676632.001]
  • [Cites] Epidemiology. 2003 Jul;14(4):386-91 [12843760.001]
  • [Cites] Int J Cancer. 2004 Feb 10;108(4):596-9 [14696126.001]
  • [Cites] Environ Health Perspect. 2004 Feb;112(2):257-65 [14754581.001]
  • [Cites] Occup Environ Med. 2004 Sep;61(9):773-8 [15317919.001]
  • [Cites] Environ Health Perspect. 2004 Oct;112(14):1386-92 [15471730.001]
  • [Cites] IARC Monogr Eval Carcinog Risk Chem Hum. 1982 May;29:1-398 [6957379.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440 [3482203.001]
  • [Cites] Environ Health Perspect. 1995 Sep;103 Suppl 6:105-10 [8549455.001]
  • [Cites] J Epidemiol Community Health. 1995 Dec;49 Suppl 2:S20-7 [8594128.001]
  • [Cites] Milbank Q. 1996;74(2):215-38 [8632735.001]
  • [Cites] Int Arch Occup Environ Health. 1997;70(1):57-60 [9258708.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1999;71 Pt 1:1-315 [10507919.001]
  • [Cites] Science. 2004 Dec 3;306(5702):1774-6 [15576619.001]
  • [Cites] J Epidemiol Community Health. 2005 Feb;59(2):101-5 [15650139.001]
  • [Cites] Cancer Invest. 2005;23(1):60-75 [15779869.001]
  • [Cites] J Epidemiol Community Health. 2005 Sep;59(9):755-60 [16100313.001]
  • [Cites] Mutat Res. 2006 Jan;612(1):14-39 [16027031.001]
  • [Cites] J Epidemiol Community Health. 2006 Feb;60(2):136-41 [16415262.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):2920-9 [16425269.001]
  • [Cites] J Expo Sci Environ Epidemiol. 2006 Nov;16(6):538-43 [16736057.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):138-45 [17366834.001]
  • [Cites] Environ Health Perspect. 2007 Oct;115(10):1388-93 [17938725.001]
  • [Cites] J Expo Sci Environ Epidemiol. 2008 Jan;18(1):45-58 [17878926.001]
  • [Cites] Cancer. 2008 Jan 15;112(2):416-32 [18074355.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Environ Health Perspect. 1995 Sep;103 Suppl 6:13-8 [8549460.001]
  • [Cites] Am J Epidemiol. 2001 Mar 1;153(5):433-43 [11226975.001]
  • (PMID = 19057714.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA128106; United States / NCI NIH HHS / CA / 1 R03 CA128106-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants
  • [Other-IDs] NLM/ PMC2592281
  • [Keywords] NOTNLM ; 1,3-butadiene / air toxics / benzene / childhood cancer / epidemiology / hazardous air pollution
  •  go-up   go-down


34. Basta NO, James PW, Craft AW, McNally RJ: Season of birth and diagnosis for childhood cancer in Northern England, 1968-2005. Paediatr Perinat Epidemiol; 2010 May;24(3):309-18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Season of birth and diagnosis for childhood cancer in Northern England, 1968-2005.
  • The chi-squared heterogeneity test was used to test for non-uniform variation.
  • There was significant sinusoidal variation based on month of birth for acute lymphoblastic leukaemia (ALL) aged 1-6 years (P = 0.04; peak in March).
  • For 0- to 14-year-old boys, there was statistically significant sinusoidal variation in month of birth for acute non-lymphocytic leukaemia (P = 0.04; peak in September) and astrocytoma (P = 0.03; peak in October).
  • This study confirms previous findings of seasonal variation around the month of birth for childhood ALL (at the peak ages) and provides further evidence of seasonal variation around month of birth for astrocytoma and around month of diagnosis for HL.
  • [MeSH-major] Astrocytoma / epidemiology. Leukemia / epidemiology. Lymphoma / epidemiology. Neoplasms / epidemiology. Seasons


35. Brenner H, Coebergh JW, Parkin DM, Izarzugaza I, Clavel J, Arndt V, Steliarova-Foucher E: Up-to-date monitoring of childhood cancer long-term survival in Europe: leukaemias and lymphomas. Ann Oncol; 2007 Sep;18(9):1569-77
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-to-date monitoring of childhood cancer long-term survival in Europe: leukaemias and lymphomas.
  • METHODS: Using the Automated Childhood Cancer Information (ACCIS) database, we carried out a period analysis of 10-year survival for the 1995-99 period.
  • RESULTS: Ten-year survival estimates for the 1995-99 period were 73% for any type of leukaemia, 78% for acute lymphoid leukaemia and 52% for acute non-lymphocytic leukaemia.
  • The corresponding 10-year survival rates for all types of lymphomas, Hodgkin lymphoma, and non-Hodgkin lymphoma were 84, 91 and 79%, respectively.
  • A large difference in prognosis is still observed between the East and other parts of Europe.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660497.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


36. Borgmann A, Zinn C, Hartmann R, Herold R, Kaatsch P, Escherich G, Möricke A, Henze G, von Stackelberg A, ALL-REZ BFM Study Group: Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. Eur J Cancer; 2008 Jan;44(2):257-68

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood.
  • PURPOSE: To investigate the cumulative incidence of and the risk factors for developing second malignant neoplasms (SMN) in children and adolescents following treatment for relapse of acute lymphocytic leukaemia (ALL).
  • METHODS: Patients (1376) up to 18 years of age with first relapse of non-B-cell ALL were treated and achieved a 2nd complete remission (CR).
  • RESULTS: Out of the 1376 patients 21 were diagnosed with SMN including non-lymphoblastic leukaemia/myelodysplastic syndrome (n=6), osteo-/Ewing's-/fibroblastic sarcoma (n=4), B-cell ALL/lymphoma (n=2), thyroid carcinoma (n=2), basal cell carcinoma, adeno carcinoma, squamous cell carcinoma, meningioma, malignant histiocytosis, glioblastoma and anaplastic astrocytoma (n=1 each).
  • [MeSH-major] Neoplasms, Second Primary / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17981026.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Mertens R; Imbach P; Pongratz E; Rupprecht T; Henze G; Wickmann L; Otte J; Bode U; Eberl W; Pekrun A; Kirschstein M; Hofmann K; Frank R; Möbius D; Andler W; Niekrens C; Breu H; Suttorp M; Göbel U; Weinmann G; Sauerbrey A; Beck JF; Janka-Schaub G; Welte K; Kulozik A; Tautz C; Graf N; Fink FM; Zintl F; Hermann J; Rupprath G; Dupuis W; Rodehüser M; Schrappe M; Berthold F; Sternschulte W; Körholz D; Schmitt K; Selle B; Gutjahr P; Dürken M; Christiansen H; Rose M; Borkhardt A; Burdach S; Jürgens H; Scheurlen W; Eggers G; Geib R; Dickerhoff R; Bielack S; Rauh W; Niethammer D; Debatin KM; Gadner H; Dohrn B; Schlegel PG; Niggli F
  •  go-up   go-down


37. Altieri A, Castro F, Bermejo JL, Hemminki K: Number of siblings and the risk of lymphoma, leukemia, and myeloma by histopathology. Cancer Epidemiol Biomarkers Prev; 2006 Jul;15(7):1281-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Number of siblings and the risk of lymphoma, leukemia, and myeloma by histopathology.
  • Epidemiologic evidence indicates that several markers of exposure to childhood infections are inversely associated with the risk of childhood leukemia and lymphomas.
  • We used the Swedish Family-Cancer Database to assess the effects of number of siblings on the risk of non-Hodgkin's (n = 7,007) and Hodgkin's lymphomas (n = 3,115), leukemias (n = 7,650), and multiple myeloma (n = 1,492) by histopathology.
  • Having four or more siblings compared with none was associated with an excess risk of childhood acute lymphoblastic leukemia [ALL; rate ratio (RR), 2.11; P(trend) = 0.001], acute monocytic leukemia (RR, 2.51; P(trend) = 0.002), and multiple myeloma (RR, 1.34; P(trend) = 0.006).
  • Having three or more older siblings compared with none decreased the risk of acute monocytic leukemia (RR, 0.35; P(trend) = 0.001) and childhood ALL (RR, 0.69; P(trend) = 0.01).
  • Acute myeloid leukemia, chronic lymphocytic leukemia, and other lymphoproliferative malignancies were not associated with number of siblings.
  • In conclusion, we found an excess risk of childhood ALL and acute monocytic leukemia in large families.
  • However, for ALL, acute monocytic leukemia, and Hodgkin's lymphoma, younger siblings were strongly protected compared with older siblings.
  • The remarkable protective effect of number of older siblings on acute monocytic leukemia is a novel finding of potential interest.
  • [MeSH-major] Birth Order. Hodgkin Disease / etiology. Leukemia / etiology. Multiple Myeloma / etiology. Siblings

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835324.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


38. Inskip PD, Curtis RE: New malignancies following childhood cancer in the United States, 1973-2002. Int J Cancer; 2007 Nov 15;121(10):2233-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New malignancies following childhood cancer in the United States, 1973-2002.
  • The objectives of our study were to quantify risks for developing new malignancies among childhood cancer survivors, identify links between particular types of first and subsequent cancer, and evaluate the possible role of treatment.
  • A cohort of 25,965 2-month survivors of childhood cancer diagnosed in the U.S. during 1973-2002 was identified and followed through SEER cancer registries.
  • Childhood cancer survivors were at nearly 6-fold risk of developing a new cancer relative to the general population (O/E = 5.9, 95% CI: 5.4-6.5).
  • Most common were subsequent primary cancers of the female breast, central nervous system, bone, thyroid gland and soft tissue, as well as cutaneous melanoma and acute non-lymphocytic leukemia (ANLL).
  • Risk of subsequent solid cancers was higher among persons whose initial treatment for childhood cancer included radiotherapy, whereas the excess of subsequent ANLL was strongly related to chemotherapy.
  • The O/E for subsequent ANLL increased with increasing calendar year of initial cancer diagnosis among survivors of cancers other than HL, most likely due to increasing use of leukemogenic drugs for solid cancers and non-Hodgkin lymphoma.
  • Childhood cancer survivors are at markedly increased risk of developing a variety of new cancers relative to the general population, but the magnitude of excess risk and specific types of second cancer vary widely by type of first cancer.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17557301.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


39. Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiaramonte R, Griffiths M, Chalmers AD, Maher ER, Latif F: The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer; 2009 Jul 01;8:42
Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias.
  • We also determined the methylation status of CpG islands associated with RASSF1-10 in a series of childhood acute lymphocytic leukaemias (ALL) and normal blood and bone marrow samples.
  • These data show epigenetic inactivation of the candidate TSGs RASSF6 and RASSF10 is an extremely frequent event in the pathogenesis of childhood leukaemia.
  • [MeSH-major] Genes, Tumor Suppressor. Monomeric GTP-Binding Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Biol. 2002 Feb 19;12(4):253-65 [11864565.001]
  • [Cites] Biochim Biophys Acta. 2009 Dec;1796(2):114-28 [19344752.001]
  • [Cites] Oncogene. 2004 Mar 25;23(13):2408-19 [14743209.001]
  • [Cites] Biochem J. 2004 Jul 15;381(Pt 2):453-62 [15109305.001]
  • [Cites] Cell. 1986 Jan 31;44(2):283-92 [3943125.001]
  • [Cites] Mamm Genome. 1996 Aug;7(8):563-74 [8679005.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8688-93 [15574778.001]
  • [Cites] Science. 2004 Dec 24;306(5705):2267-70 [15618521.001]
  • [Cites] Leukemia. 2005 Mar;19(3):415-9 [15674422.001]
  • [Cites] Dev Cell. 2005 Mar;8(3):413-25 [15737936.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3497-508 [15867337.001]
  • [Cites] Oncogene. 2005 Jun 2;24(24):3987-94 [15806169.001]
  • [Cites] Mol Cell. 2005 Jun 10;18(6):637-50 [15949439.001]
  • [Cites] Nat Genet. 2005 Dec;37(12):1323-32 [16311596.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):950-6 [16404744.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):4557-63 [16344548.001]
  • [Cites] Dis Markers. 2007;23(1-2):73-87 [17325427.001]
  • [Cites] Exp Cell Res. 2007 Apr 15;313(7):1484-95 [17367779.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep;1776(1):58-85 [17692468.001]
  • [Cites] Oncogene. 2007 Sep 13;26(42):6203-11 [17404571.001]
  • [Cites] Mol Cell. 2007 Sep 21;27(6):962-75 [17889669.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):26-33 [17910045.001]
  • [Cites] Mol Biol Cell. 2008 Apr;19(4):1772-82 [18272789.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):11-22 [12509763.001]
  • (PMID = 19570220.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G120/844
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RASSF6 protein, human; EC 3.6.5.2 / Monomeric GTP-Binding Proteins
  • [Other-IDs] NLM/ PMC2711046
  •  go-up   go-down


40. Sorich MJ, Pottier N, Pei D, Yang W, Kager L, Stocco G, Cheng C, Panetta JC, Pui CH, Relling MV, Cheok MH, Evans WE: In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med; 2008 Apr 15;5(4):e83
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile.
  • BACKGROUND: Childhood acute lymphoblastic leukemia (ALL) is the most common cancer in children, and can now be cured in approximately 80% of patients.
  • Although MTX has been extensively studied for many years, relatively little is known about mechanisms of de novo resistance in primary cancer cells, including leukemia cells.
  • METHODS AND FINDINGS: We utilized measures of decreased circulating leukemia cells of 293 newly diagnosed children after initial "up-front" in vivo MTX treatment (1 g/m(2)) to elucidate interpatient differences in the antileukemic effects of MTX.
  • We identified 48 genes and two cDNA clones whose expression was significantly related to the reduction of circulating leukemia cells after initial in vivo treatment with MTX.
  • CONCLUSIONS: Together, these data provide new insights into the genomic basis of MTX resistance and interpatient differences in MTX response, pointing to new strategies to overcome MTX resistance in childhood ALL.
  • TRIAL REGISTRATIONS: Total XV, Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia, http://www.ClinicalTrials.gov (NCT00137111); Total XIIIBH, Phase III Randomized Study of Antimetabolite-Based Induction plus High-Dose MTX Consolidation for Newly Diagnosed Pediatric Acute Lymphocytic Leukemia at Intermediate or High Risk of Treatment Failure (NCI-T93-0101D); Total XIIIBL, Phase III Randomized Study of Antimetabolite-Based Induction plus High-Dose MTX Consolidation for Newly Diagnosed Pediatric Acute Lymphocytic Leukemia at Lower Risk of Treatment Failure (NCI-T93-0103D).
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Drug Resistance, Neoplasm. Gene Expression Profiling. Methotrexate / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Nature. 2004 May 27;429(6990):464-8 [15164072.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S124-6 [15124703.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Bioinformatics. 2004 Jan 1;20(1):93-9 [14693814.001]
  • [Cites] JAMA. 2003 Oct 15;290(15):2001-7 [14559953.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Sep;25(9):688-95 [12972803.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]
  • [Cites] Vitam Horm. 2003;66:403-56 [12852262.001]
  • [Cites] Nat Genet. 2003 May;34(1):85-90 [12704389.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):775-81 [12618889.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1240-7 [12149204.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2423-9 [12114448.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1271-7 [17456722.001]
  • [Cites] Mol Pharmacol. 2006 Nov;70(5):1832-9 [16936229.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):331-42 [17010674.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):117-29 [16491071.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4752-8 [15713801.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):375-86 [15837626.001]
  • [Cites] Blood. 2005 Jan 15;105(2):821-6 [15388585.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):110-7 [15630450.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Biochem Pharmacol. 1999 Aug 15;58(4):539-55 [10413291.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2532-5 [10363967.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1067-74 [9920857.001]
  • [Cites] J Biol Chem. 1980 Jun 25;255(12):5776-88 [6892914.001]
  • [Cites] J Clin Invest. 1985 Sep;76(3):907-12 [2413074.001]
  • [Cites] Cancer Res. 1988 Oct 15;48(20):5638-44 [2458828.001]
  • [Cites] Blood. 1990 Jul 1;76(1):44-9 [1694703.001]
  • [Cites] Blood. 1990 Oct 15;76(8):1449-63 [2207320.001]
  • [Cites] Blood. 1994 Jul 15;84(2):564-9 [7517720.001]
  • [Cites] J Clin Invest. 1994 Nov;94(5):1996-2001 [7525652.001]
  • [Cites] J Clin Invest. 1996 Jan 1;97(1):73-80 [8550853.001]
  • [Cites] N Engl J Med. 1996 Oct 3;335(14):1041-8 [8793930.001]
  • [Cites] J Natl Cancer Inst. 1996 Sep 18;88(18):1255-6 [8797761.001]
  • [Cites] Nat Genet. 1996 Dec;14(4):457-60 [8944026.001]
  • [Cites] Nat Genet. 1999 Jan;21(1 Suppl):20-4 [9915496.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2286-94 [11187920.001]
  • [Cites] Haematologica. 2001 Feb;86(2):121-7 [11224479.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7225-32 [11585759.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15149-54 [11742071.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3144-50 [12036927.001]
  • [Cites] Biochim Biophys Acta. 2002 Jul 18;1587(2-3):164-73 [12084458.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • (PMID = 18416598.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00137111
  • [Grant] United States / NCI NIH HHS / CA / R37 CA36401; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / R01 CA078224; United States / NCI NIH HHS / CA / R37 CA036401; United States / NIGMS NIH HHS / GM / U01 GM61393; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R01 CA051001; United States / NCI NIH HHS / CA / R01 CA78224; United States / NCI NIH HHS / CA / R01 CA51001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2292747
  •  go-up   go-down


41. Hallböök H, Gustafsson G, Smedmyr B, Söderhäll S, Heyman M, Swedish Adult Acute Lymphocytic Leukemia Group, Swedish Childhood Leukemia Group: Treatment outcome in young adults and children &gt;10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer; 2006 Oct 1;107(7):1551-61
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol.
  • BACKGROUND: Several studies have reported a more favorable outcome for teenagers and young adults with acute lymphoblastic leukemia (ALL) when they were treated in pediatric oncology departments compared with adult hematology departments.
  • METHODS: In Sweden during the 1990s, adolescents with ALL were treated in a pediatric oncology unit or in an adult hematologic unit, depending on the initial referral.
  • In the current national, comparative, retrospective study, patients with ALL aged 10 years to 40 years who were treated either according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL protocol (1992-2000) (NOPHO-92 protocol) or according to the Swedish Adult ALL Group protocol (1994-2000) (Adult protocol) were included.
  • CONCLUSIONS: The NOPHO-92 protocol resulted in a better outcome than the Adult protocol; therefore, adolescents may benefit from the pediatric protocol treatment strategy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / mortality. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / mortality

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16955505.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


42. Korenkov AI, Imhof HG, Brandner S, Taub E, Huguenin PU, Gaab MR, Yonekawa Y: Growth retardation and bilateral cataracts followed by anaplastic meningioma 23 years after high-dose cranial and whole-body irradiation for acute lymphoblastic leukemia: case report and review of the literature. J Neurooncol; 2005 Sep;74(2):195-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth retardation and bilateral cataracts followed by anaplastic meningioma 23 years after high-dose cranial and whole-body irradiation for acute lymphoblastic leukemia: case report and review of the literature.
  • We report a case of meningioma diagnosed 23 years after high-dose cranial and whole-body irradiation for the treatment of acute lymphocytic leukemia (ALL).
  • Radiation-induced meningiomas are more commonly malignant, more commonly multiple, and more likely to recur after resection than non-radiation-induced meningiomas.
  • Survivors of childhood ALL treated with high-dose cranial irradiation are at risk both for early radiation injury in radiosensitive organs, such as the lens and pituitary gland, and for the later development of a radiation-induced meningioma.
  • [MeSH-major] Cataract / etiology. Cranial Irradiation / adverse effects. Growth Disorders / etiology. Meningeal Neoplasms / etiology. Meningioma / etiology. Neoplasms, Radiation-Induced / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy


43. Mulrooney DA, Ness KK, Neglia JP, Whitton JA, Green DM, Zeltzer LK, Robison LL, Mertens AC: Fatigue and sleep disturbance in adult survivors of childhood cancer: a report from the childhood cancer survivor study (CCSS). Sleep; 2008 Feb;31(2):271-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatigue and sleep disturbance in adult survivors of childhood cancer: a report from the childhood cancer survivor study (CCSS).
  • STUDY OBJECTIVE: To examine the prevalence of and risk factors for fatigue and sleep disturbance among adult survivors of childhood cancer.
  • DESIGN: Retrospective cohort of childhood cancer survivors.
  • SETTING: Twenty-six academic institutions treating childhood cancer.
  • PARTICIPANTS: Two thousand six hundred forty-five survivors of childhood acute lymphocytic leukemia, central nervous system tumors, Hodgkin lymphoma, soft-tissue sarcomas, or bone tumors diagnosed before age 21, surviving at least 5 years from diagnosis, and a 500-sibling comparison group.
  • CONCLUSION: Because of the large sample size, we detected more objectively reported fatigue, sleep disturbance, and daytime sleepiness among adult survivors of childhood cancer.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • MedlinePlus Health Information. consumer health - Fatigue.
  • MedlinePlus Health Information. consumer health - Sleep Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2003 Jan;39(2):204-14 [12509953.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Oncologist. 2003;8 Suppl 1:5-9 [12626781.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1249-54 [12663711.001]
  • [Cites] J Pain Symptom Manage. 2003 Apr;25(4):307-18 [12691682.001]
  • [Cites] Pediatrics. 2003 Jul;112(1 Pt 1):e46-54 [12837905.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3255-61 [12947060.001]
  • [Cites] Eur J Cancer. 2003 Oct;39(15):2179-86 [14522376.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4731-9 [14557448.001]
  • [Cites] Eur J Endocrinol. 2004 Apr;150(4):503-10 [15080780.001]
  • [Cites] Psychiatry Res. 1989 May;28(2):193-213 [2748771.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):743-53 [10673515.001]
  • [Cites] J Pain Symptom Manage. 2000 Feb;19(2):91-9 [10699536.001]
  • [Cites] J Pain Symptom Manage. 2000 Jul;20(1):12-8 [10946164.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32 [10999813.001]
  • [Cites] Ann Oncol. 2000 Aug;11(8):971-5 [11038033.001]
  • [Cites] Support Care Cancer. 2001 Jan;9(1):11-7 [11147137.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):895-908 [11157043.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3385-91 [11454886.001]
  • [Cites] J Child Neurol. 2001 Oct;16(10):767-70 [11669353.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):528-38 [11900238.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Aug;87(8):3993-6 [12161549.001]
  • [Cites] Am J Obstet Gynecol. 2002 Oct;187(4):1070-80 [12389007.001]
  • [Cites] Cancer. 2002 Dec 1;95(11):2431-41 [12436452.001]
  • [Cites] Sleep. 1991 Dec;14(6):540-5 [1798888.001]
  • [Cites] Neuropediatrics. 1992 Feb;23(1):39-45 [1565216.001]
  • [Cites] J Epidemiol Community Health. 1992 Apr;46(2):92-7 [1583440.001]
  • [Cites] Med Care. 1992 Jun;30(6):473-83 [1593914.001]
  • [Cites] Sleep. 1992 Aug;15(4):376-81 [1519015.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):547-56 [9053476.001]
  • [Cites] J Pain Symptom Manage. 1997 Feb;13(2):63-74 [9095563.001]
  • [Cites] Support Care Cancer. 1998 Mar;6(2):101-8 [9540167.001]
  • [Cites] J Psychosom Res. 1998 Jul;45(1):5-13 [9720850.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):253-61 [10458240.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5501-10 [16110010.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6587-95 [16170166.001]
  • [Cites] Ann Intern Med. 2005 Nov 1;143(9):639-47 [16263886.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):663-73 [12548609.001]
  • (PMID = 18274275.001).
  • [ISSN] 0161-8105
  • [Journal-full-title] Sleep
  • [ISO-abbreviation] Sleep
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA055727; United States / NCI NIH HHS / CA / U24 CA 55727
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2225565
  •  go-up   go-down


44. Helton SC, Corwyn RF, Bonner MJ, Brown RT, Mulhern RK: Factor analysis and validity of the Conners Parent and Teacher Rating Scales in childhood cancer survivors. J Pediatr Psychol; 2006 Mar;31(2):200-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factor analysis and validity of the Conners Parent and Teacher Rating Scales in childhood cancer survivors.
  • OBJECTIVE: To examine the factor structure of the Conners Parent Rating Scale-Revised: Short Form (CPRS-R:S) and the Conners Teacher Rating Scale-Revised: Short Form (CTRS-R:S) in children who are long-term survivors of acute lymphocytic leukemia (ALL) or brain tumors (BT)and who have received central nervous system directed treatment.
  • Although significantly correlated, the CPRS-R:S and CTRS-R:S are not interchangeable in the assessment of survivors of childhood cancer.
  • [MeSH-major] Attention. Brain Neoplasms / complications. Cognition Disorders / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Psychological Tests

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16467320.001).
  • [ISSN] 0146-8693
  • [Journal-full-title] Journal of pediatric psychology
  • [ISO-abbreviation] J Pediatr Psychol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA21765; United States / NCI NIH HHS / CA / R01 CA78957; United States / NCI NIH HHS / CA / U01 CA81445
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


45. Van Maele-Fabry G, Lantin AC, Hoet P, Lison D: Childhood leukaemia and parental occupational exposure to pesticides: a systematic review and meta-analysis. Cancer Causes Control; 2010 Jun;21(6):787-809
MedlinePlus Health Information. consumer health - Pesticides.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood leukaemia and parental occupational exposure to pesticides: a systematic review and meta-analysis.
  • OBJECTIVE: To conduct a systematic review and meta-analysis of published studies on the association between parental occupational exposure to pesticides and childhood leukaemia.
  • RESULTS: No statistically significant association between childhood leukaemia and parental occupation as farmers/agricultural workers was observed.
  • When exposure to pesticides was stipulated, positive associations were reported for maternal exposure for all studies combined (mRR: 1.62; 95% CI: 1.22-2.16), in all exposure windows considered and for acute non-lymphocytic leukaemia (ANLL).
  • CONCLUSIONS: The strongest evidence of an increased risk of childhood leukaemia comes from studies with maternal occupational exposure to pesticides.
  • [MeSH-major] Leukemia / chemically induced. Occupational Exposure / adverse effects. Pesticides / adverse effects

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20467891.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Disinfectants; 0 / Pesticides
  • [Number-of-references] 76
  •  go-up   go-down


46. Coebergh JW, Reedijk AM, de Vries E, Martos C, Jakab Z, Steliarova-Foucher E, Kamps WA: Leukaemia incidence and survival in children and adolescents in Europe during 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer; 2006 Sep;42(13):2019-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukaemia incidence and survival in children and adolescents in Europe during 1978-1997. Report from the Automated Childhood Cancer Information System project.
  • Lymphoid leukaemia (LL) accounted for 81%, acute non-lymphocytic leukaemia (ANLL) for 15%, chronic myeloid leukaemia (CML) for 1.5% and unspecified leukaemia for 1.3% of cases.
  • Adjusted for sex and age, incidence of childhood LL was significantly lower in the East and higher in the North than in the British Isles.
  • Similar differences in survival between children and adolescents were observed for LL, much less so for ANLL.
  • For children with ANLL most improvements in survival were observed in the 1990s.
  • [MeSH-major] Databases, Factual / statistics & numerical data. Leukemia / epidemiology

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919768.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


47. Stack M, Walsh PM, Comber H, Ryan CA, O'Lorcain P: Childhood cancer in Ireland: a population-based study. Arch Dis Child; 2007 Oct;92(10):890-7
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood cancer in Ireland: a population-based study.
  • BACKGROUND: Population-based studies of childhood cancer incidence, survival and mortality make an important contribution to monitoring the successful implementation of new treatment guidelines and to understanding the epidemiology of these diseases.
  • Observed 5-year survival in Ireland (79% overall) was slightly higher than European and US averages, and was significantly higher for acute non-lymphocytic leukaemia (67%) and (compared with the USA) significantly lower for Hodgkin lymphoma (83%).
  • Rates of childhood cancer mortality have declined markedly since the 1950s.
  • CONCLUSIONS: Data presented here are in line with other developed countries and suggest major improvements in treatment and consequent survival.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stat Med. 2000 Feb 15;19(3):335-51 [10649300.001]
  • [Cites] Eur J Cancer. 2001 Apr;37(6):785-809 [11311655.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v119-27 [14684502.001]
  • [Cites] Ir Med J. 1992 Jun;85(2):50-2 [1628939.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2130-8 [16304572.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 16;91(12):1051-8 [10379968.001]
  • [Cites] Lancet. 2004 Dec 11-17;364(9451):2097-105 [15589307.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3742-51 [15923571.001]
  • [Cites] Ir Med J. 1995 May-Jun;88(3):96-8 [7635688.001]
  • (PMID = 17566053.001).
  • [ISSN] 1468-2044
  • [Journal-full-title] Archives of disease in childhood
  • [ISO-abbreviation] Arch. Dis. Child.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2083220
  •  go-up   go-down


48. Robazzi TC, Silva LR, Mendonça N, Barreto JH: Gastrointestinal manifestations as initial presentation of acute leukemias in children and adolescents. Acta Gastroenterol Latinoam; 2008 Jun;38(2):126-32
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal manifestations as initial presentation of acute leukemias in children and adolescents.
  • OBJECTIVE: this study aimed to determine the prevalence and characteristics of gastrointestinal manifestations on initial clinical presentation of acute leukemias (AL) in childhood.
  • RESULTS: acute lymphoid leukemia (ALL) was diagnosed in 273 (77.1%) patients and acute non-lymphocytic leukemia (AML) in 81 (22.9%).
  • CONCLUSIONS: gastrointestinal symptoms are not very well-documented as initial manifestation of leukemia in children and should be considered on the differential diagnosis of gastrointestinal symptoms of unknown etiology in children.
  • [MeSH-major] Gastrointestinal Diseases / etiology. Leukemia, Myeloid, Acute / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697407.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


49. Chang P, Kang M, Xiao A, Chang J, Feusner J, Buffler P, Wiemels J: FLT3 mutation incidence and timing of origin in a population case series of pediatric leukemia. BMC Cancer; 2010 Sep 27;10:513
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FLT3 mutation incidence and timing of origin in a population case series of pediatric leukemia.
  • BACKGROUND: Mutations in FLT3 result in activated tyrosine kinase activity, cell growth stimulation, and a poor prognosis among various subtypes of leukemia.
  • We evaluated the prevalence and timing of origin of FLT3 mutations in a population series of childhood leukemia patients from Northern California.
  • METHODS: We screened and sequenced FLT3 mutations (point mutations and internal tandem duplications, ITDs) among 517 childhood leukemia patients, and assessed whether these mutations occurred before or after birth using sensitive "backtracking" methods.
  • RESULTS: We determined a mutation prevalence of 9 of 73 acute myeloid leukemias (AMLs, 12%) and 9 of 441 acute lymphocytic leukemias (ALLs, 2%).

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):578-81 [16537719.001]
  • [Cites] Blood. 2010 Oct 14;116(15):2752-8 [20592250.001]
  • [Cites] Am J Epidemiol. 2006 Jun 15;163(12):1091-100 [16597704.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1217-20 [16642044.001]
  • [Cites] Leuk Res. 2006 Sep;30(9):1085-9 [16533526.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):26-33 [17910045.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):64-70 [17943971.001]
  • [Cites] J Natl Cancer Inst Monogr. 2008;(39):87-90 [18648011.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6803-9 [18701506.001]
  • [Cites] Leukemia. 2008 Sep;22(9):1692-7 [18548099.001]
  • [Cites] Radiat Prot Dosimetry. 2008;132(2):212-9 [18940823.001]
  • [Cites] Methods Mol Biol. 2009;538:7-27 [19277581.001]
  • [Cites] Drug Resist Updat. 2009 Jun;12(3):81-9 [19467916.001]
  • [Cites] Lancet. 1999 Oct 30;354(9189):1499-503 [10551495.001]
  • [Cites] Blood. 2000 Apr 15;95(8):2722-4 [10753857.001]
  • [Cites] Blood. 2000 Jul 1;96(1):264-8 [10891460.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2992-6 [11929791.001]
  • [Cites] Br J Cancer. 2002 May 6;86(9):1419-24 [11986774.001]
  • [Cites] Environ Health Perspect. 2002 Sep;110(9):955-60 [12204832.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2393-8 [12239147.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15101-6 [12415113.001]
  • [Cites] Semin Hematol. 2002 Oct;39(4 Suppl 3):6-11 [12447846.001]
  • [Cites] Genes Chromosomes Cancer. 2003 May;37(1):36-43 [12661004.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):650-65 [12951584.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2321-33 [12791663.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1085-8 [14504097.001]
  • [Cites] Blood. 2004 May 1;103(9):3544-6 [14670924.001]
  • [Cites] Leukemia. 1996 Feb;10(2):213-24 [8637229.001]
  • [Cites] Genes Chromosomes Cancer. 1996 May;16(1):40-5 [9162196.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4 [9391133.001]
  • [Cites] Leukemia. 2005 Mar;19(3):415-9 [15674422.001]
  • [Cites] Med Oncol. 2009 Dec;26(4):460-2 [19085113.001]
  • [Cites] Leukemia. 2010 May;24(5):924-31 [20237506.001]
  • [Cites] Blood Cells Mol Dis. 2010 Oct 15;45(3):186-91 [20688547.001]
  • [Cites] BMC Cancer. 2006;6:100 [16630339.001]
  • (PMID = 20875128.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA089032; United States / NCI NIH HHS / CA / R01 CA089032-06; United States / NIEHS NIH HHS / ES / P42ES0470; United States / NCI NIH HHS / CA / R01 CA089032-05; United States / NCI NIH HHS / CA / R01CA89032; United States / NIEHS NIH HHS / ES / R01ES09137
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Other-IDs] NLM/ PMC2955609
  •  go-up   go-down


50. Siviero-Miachon AA, Spinola-Castro AM, Guerra-Junior G: Detection of metabolic syndrome features among childhood cancer survivors: a target to prevent disease. Vasc Health Risk Manag; 2008;4(4):825-36
MedlinePlus Health Information. consumer health - Metabolic Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of metabolic syndrome features among childhood cancer survivors: a target to prevent disease.
  • Some pediatric disease states are at risk for premature cardiovascular disease, with clinical coronary events occurring very early in adult life.
  • Survivors of specific pediatric cancer groups, particularly acute lymphocytic leukemia, central nervous system tumors, sarcomas, lymphomas, testicular cancer, and following bone marrow transplantation, may develop metabolic syndrome traits due to: hormonal deficiencies (growth hormone deficiency, thyroid dysfunction, and gonadal failure), drug or radiotherapy damage, endothelial impairment, physical inactivity, adipose tissue dysfunction, and/or drug-induced magnesium deficiency.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Lymphoma Myeloma. 2005 Sep;6(2):122-30 [16231850.001]
  • [Cites] J Diabetes Complications. 2006 Mar-Apr;20(2):121-32 [16504841.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Feb;19(2):121-7 [16562584.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(12):1109-17 [16699534.001]
  • [Cites] J Natl Cancer Inst. 2006 Jul 5;98(13):890-6 [16818852.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1793-801 [16823477.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1303-12 [16894525.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Oct;23(7):424-30 [11878576.001]
  • [Cites] Cancer Treat Rev. 2002 Aug;28(4):195-214 [12363460.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):611-6 [12574189.001]
  • [Cites] Rev Endocr Metab Disord. 2003 Mar;4(1):23-32 [12618557.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4401-7 [16954158.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2006 Nov;18(9):710-8 [17100159.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Dec;17(6):475-86 [17118696.001]
  • [Cites] Circulation. 2006 Dec 12;114(24):2710-38 [17130340.001]
  • [Cites] Pediatr Diabetes. 2006 Dec;7(6):311-21 [17212598.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1765-72 [17047152.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1183-9 [17401007.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 May;29(5):309-14 [17483708.001]
  • [Cites] Acta Oncol. 2007;46(4):480-9 [17497315.001]
  • [Cites] Lancet. 2007 Jun 23;369(9579):2059-61 [17586288.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1356-63 [17627001.001]
  • [Cites] Eur J Endocrinol. 2000 Aug;143(2):243-50 [10913944.001]
  • [Cites] Med Pediatr Oncol. 2000 Aug;35(2):91-5 [10918229.001]
  • [Cites] Endocr Rev. 2000 Dec;21(6):697-738 [11133069.001]
  • [Cites] JAMA. 2001 May 16;285(19):2486-97 [11368702.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2775-8 [11397886.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5245-51 [11701685.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2953-60 [12885815.001]
  • [Cites] Arch Pediatr Adolesc Med. 2003 Aug;157(8):821-7 [12912790.001]
  • [Cites] Endocr Pract. 2003 May-Jun;9(3):237-52 [12924350.001]
  • [Cites] Diabetes Care. 2003 Nov;26(11):3160-7 [14578255.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5227-31 [14602754.001]
  • [Cites] Oncol Rep. 2004 Jan;11(1):185-9 [14654924.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):81-6 [14715831.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):108-13 [14715836.001]
  • [Cites] Circulation. 2004 Jan 27;109(3):433-8 [14744958.001]
  • [Cites] Arch Intern Med. 2004 May 24;164(10):1066-76 [15159263.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2362-74 [15175438.001]
  • [Cites] Pediatrics. 2004 Aug;114(2 Suppl 4th Report):555-76 [15286277.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3558-62 [15337805.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Oct;89(10):5003-12 [15472198.001]
  • [Cites] Circulation. 2004 Oct 19;110(16):2494-7 [15477412.001]
  • [Cites] Diabetes. 1988 Dec;37(12):1595-607 [3056758.001]
  • [Cites] Pediatrics. 1992 Mar;89(3 Pt 2):525-84 [1538956.001]
  • [Cites] BMJ. 1995 Jul 15;311(6998):171-4 [7613432.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):3051-5 [8768873.001]
  • [Cites] Pediatrics. 1996 Oct;98(4 Pt 1):649-58 [8885941.001]
  • [Cites] Eur J Endocrinol. 1998 Jan;138(1):89-91 [9461323.001]
  • [Cites] Diabet Med. 1998 Jul;15(7):539-53 [9686693.001]
  • [Cites] Int J Obes Relat Metab Disord. 1998 Dec;22(12):1145-58 [9877249.001]
  • [Cites] Prev Med. 1998 Nov-Dec;27(6):879-90 [9922071.001]
  • [Cites] Diabet Med. 1999 May;16(5):442-3 [10342346.001]
  • [Cites] J Pediatr Endocrinol Metab. 2004 Oct;17(10):1405-13 [15526719.001]
  • [Cites] Curr Opin Pediatr. 2007 Aug;19(4):480-7 [17630615.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Aug;29(8):529-34 [17762493.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Oct;92(10):3816-21 [17652222.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Nov;29(11):776-82 [17984698.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2):341-6 [17918262.001]
  • [Cites] Pediatr Blood Cancer. 2008 Feb;50(2 Suppl):462-7; discussion 468 [18064658.001]
  • [Cites] Am J Clin Nutr. 2007 Sep;86(3):s817-9 [18265474.001]
  • [Cites] Am J Clin Nutr. 2007 Sep;86(3):s820-2 [18265475.001]
  • [Cites] Am J Clin Nutr. 2007 Sep;86(3):s867-71 [18265480.001]
  • [Cites] Cancer. 2000 May 1;88(9):2116-21 [10813724.001]
  • [Cites] Diabetes Care. 2000 Mar;23(3):381-9 [10868870.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Dec;61(6):683-91 [15579181.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):589-602 [15613441.001]
  • [Cites] Bone Marrow Transplant. 2005 Jan;35(2):209-10 [15558043.001]
  • [Cites] Metabolism. 2005 Mar;54(3):321-9 [15736109.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):2659-65 [15713715.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3718-25 [15738540.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):81-9 [15994749.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Sep;27(9):499-501 [16189445.001]
  • (PMID = 19065999.001).
  • [ISSN] 1176-6344
  • [Journal-full-title] Vascular health and risk management
  • [ISO-abbreviation] Vasc Health Risk Manag
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 79
  • [Other-IDs] NLM/ PMC2597761
  •  go-up   go-down


51. Lawce H, Olson S: FISH testing for deletions of chromosome 6q21 and 6q23 in hematologic neoplastic disorders. J Assoc Genet Technol; 2009;35(4):167-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Deletions of chromosome 6q are found in many types of cancer, including melanoma, prostate cancer, fibroadenomas, and carcinoma of breast and other sites.
  • Chromosome 6q deletions are also commonly found in lymphoid malignancies such as acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), multiple myeloma (MM), mantle zone lymphoma (MZL), and Waldenström's macroglobulinemia (WM).
  • In childhood B- and T-cell ALL a deletion of 6q is the hallmark of a neutral prognosis; however, it may be cytogenetically obscure or cryptic, requiring interphase FISH analysis.
  • In adult ALL it indicates a favorable prognosis, but in CLL, B-cell small lymphocytic lymphoma (SLL), WM, and MM it has a poor prognosis.
  • We report the results of the first three patients in our laboratory with deletions of 6q in lymphoid malignancies using this cocktail.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952391.001).
  • [ISSN] 1523-7834
  • [Journal-full-title] Journal of the Association of Genetic Technologists
  • [ISO-abbreviation] J Assoc Genet Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement